GlassScriptPhysician profile
Mark Ko Yamanaka
NPI 1013004852
$4,398.62
in general payments reported to CMS, 2019-2025
32 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $244 · 2021: $55.24 · 2022: $22.32 · 2023: $397 · 2024: $1,260 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,264 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,263.63 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $753.60 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Glaxosmithkline, LLC. | $734.75 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.59 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $397.35 | 2019-2025 | Airsupra, Breztri |
| Grifols USA, LLC | $269.27 | 2019-2025 | Prolastin-C Liquid |
| Philips North America LLC | $218.21 | 2019-2025 | Encore, (O58) Sleep Respiratory Care Und |
| Regeneron Healthcare Solutions, INC. | $203.88 | 2024-2025 | Dupixent |
| Insmed, INC. | $189.39 | 2019-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $187.46 | 2024-2025 | Glassia |
| Viatris Specialty LLC | $163.27 | 2025 | Yupelri |
| Abiomed | $120.26 | 2025 | |
| Mylan Specialty L.P. | $119.77 | 2019-2020 | |
| Baxter Healthcare | $104.62 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $66.68 | 2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $54.52 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $40.41 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $33.46 | 2025 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $29.66 | 2025 | Nuzyra |
| Shionogi INC | $27.97 | 2025 | Fetroja |
| Inspire Medical Systems, INC. | $27.59 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $27.37 | 2025 | Winrevair |
| Vifor Pharma, INC. | $26.21 | 2024 | Zemaira |
| Abbvie INC. | $22.95 | 2023 | Avycaz |
| 3b Medical, INC. | $22.57 | 2025 | Luna |
| Genzyme Corporation | $20.85 | 2025 | |
| Verona Pharma, INC. | $20.68 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $19.91 | 2019 | |
| Genentech USA, INC. | $19.40 | 2019 | |
| United Therapeutics Corporation | $19.05 | 2021 | |
| Chiesi USA, INC. | $18.22 | 2023 | Cleviprex |
| Allergan, INC. | $17.75 | 2019 | |
| Lilly USA, LLC | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Yamanaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.